Furthermore, a recent study has revealed Gab1 not only as a convergence point between c-MET and EGFR pathways, but also suggests that Gab1 cooperates with MET amplification in lung cancer cells, which have become resistant towards the EGFR inhibitor gefitinib [204]. This evidence concerns the gene GAB1 and lung carcinoma.